EGFR and urogenital neoplasm: Overall, 8.5% of patients harbored an EGFR amplification in their blood-derived cfDNA, with EGFR amplifications being most common in colorectal cancer (16.3% of patients), NSCLC (9.0%), genitourinary cancers (8.1%), cutaneous tumors (7.4%), and breast malignancies (7.3%).